Oncology

News

Corcept shares surge on FDA approval of Lifyorli, a first-in-class selective glucocorticoid receptor antagonist for ovarian cancer.

News

MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff has continued with a $6.7bn bid to acquire Terns Pharma.

News

Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.

News

MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer.

News

Dizal's Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of lung cancer.

News

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.